The Use of Prognostic Factors in Inflammatory Bowel Diseases

被引:23
作者
Billiet T. [1 ]
Ferrante M. [1 ]
Van Assche G. [1 ]
机构
[1] Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, Leuven
关键词
Crohn’s disease; Genetics; IBD; Personalized medicine; Prognostic factors; Serological markers; Ulcerative colitis;
D O I
10.1007/s11894-014-0416-y
中图分类号
学科分类号
摘要
The disease spectrum and natural course of Crohn’s disease and ulcerative colitis are highly variable. The majority of Crohn’s disease patients will require surgery at a certain stage in their disease compared to only a fraction of the ulcerative colitis patients. Similarly, some patients are destined to experience an indolent disease course while others will require early intensive therapy. Ideally, these subtypes of patients should be identified as early as possible with the help of reliable prognostic factors in order to guide personalized therapeutic decisions. In this review, the authors focused on the most relevant reports on the use of different prognostic factors to predict disease course, postoperative recurrence and response to therapy in patients with inflammatory bowel disease. The last 15 years have seen a wealth of novel genetic and serological markers of disease severity. Nevertheless, none of these markers have proven to be superior to careful clinical phenotyping and endoscopic features early in the disease course. Future attempts should apply an integrated approach that unites clinical, serological and (epi)genetic information with environmental influences, with a clear focus on the microbiome to ultimately identify molecular-based and clinically relevant subgroups. © 2014, Springer Science+Business Media New York.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 139 条
[41]  
Nunes T., Etchevers M.J., Domenech E., Garcia-Sanchez V., Ber Y., Penalva M., Et al., Smoking does influence disease behaviour and impacts the need for therapy in Crohn’s disease in the biologic era, Aliment Pharmacol Ther, 38, 7, pp. 752-760, (2013)
[42]  
Lawrance I.C., Murray K., Batman B., Gearry R.B., Grafton R., Krishnaprasad K., Et al., Crohn’s disease and smoking: is it ever too late to quit?, J Crohns Colitis, 7, 12, pp. e665-e671, (2013)
[43]  
Lakatos P.L., Vegh Z., Lovasz B.D., David G., Pandur T., Erdelyi Z., Et al., Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort, Inflamm Bowel Dis, 19, 5, pp. 1010-1017, (2013)
[44]  
Hoie O., Wolters F., Riis L., Aamodt G., Solberg C., Bernklev T., Et al., Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort, Am J Gastroenterol, 102, 8, pp. 1692-1701, (2007)
[45]  
Hoie O., Wolters F.L., Riis L., Bernklev T., Aamodt G., Clofent J., Et al., Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years, Gastroenterology, 132, 2, pp. 507-515, (2007)
[46]  
Solberg I.C., Lygren I., Jahnsen J., Aadland E., Hoie O., Cvancarova M., Et al., Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study), Scand J Gastroenterol, 44, 4, pp. 431-440, (2009)
[47]  
Gower-Rousseau C., Dauchet L., Vernier-Massouille G., Tilloy E., Brazier F., Merle V., Et al., The natural history of pediatric ulcerative colitis: a population-based cohort study, Am J Gastroenterol, 104, 8, pp. 2080-2088, (2009)
[48]  
Burisch J., Pedersen N., Cukovic-Cavka S., Turk N., Kaimakliotis I., Duricova D., Et al., Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort, Inflamm Bowel Dis, 20, 1, pp. 36-46, (2014)
[49]  
Ng S.C., Tang W., Ching J.Y., Wong M., Chow C.M., Hui A.J., Et al., Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study, Gastroenterology, 145, 1, pp. 158-165, (2013)
[50]  
Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., Et al., Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease, Gastroenterology, 131, 2, pp. 366-378, (2006)